MaxCyte Share Forecast, Price & News

GBX 1,075
0.00 (0.00 %)
(As of 08/4/2021 04:38 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume269,977 shs
Average Volume204,645 shs
Market Capitalization£914.28 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MaxCyte logo

About MaxCyte

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.


MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,180.00
MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,180.00
August 2, 2021 |  americanbankingnews.com
MaxCyte, Inc. - Pricing of Offering and Approval to List on Nasdaq
MaxCyte, Inc. - Pricing of Offering and Approval to List on Nasdaq
August 2, 2021 |  proactiveinvestors.com.au
MaxCyte, Inc. : Price Monitoring Extension
MaxCyte, Inc. : Price Monitoring Extension
July 31, 2021 |  markets.businessinsider.com
Dole Drops in IPO. 7 Biotechs Went Public, Too.
Dole Drops in IPO. 7 Biotechs Went Public, Too.
July 30, 2021 |  finance.yahoo.com
MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,064.30
MaxCyte (LON:MXCT) Reaches New 1-Year High at $1,064.30
July 12, 2021 |  americanbankingnews.com
Is MaxCyte (LON:MXCT) Using Debt In A Risky Way?
Is MaxCyte (LON:MXCT) Using Debt In A Risky Way?
June 29, 2021 |  finance.yahoo.com
MaxCyte, Inc. (MXCT.L)
MaxCyte, Inc. (MXCT.L)
June 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.41 out of 5 stars

Analyst Opinion: 2.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MaxCyte (LON:MXCT) Frequently Asked Questions

Is MaxCyte a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte
or view top-rated stocks.

What stocks does MarketBeat like better than MaxCyte?

Wall Street analysts have given MaxCyte a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MaxCyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MaxCyte's next earnings date?

MaxCyte is scheduled to release its next quarterly earnings announcement on Monday, September 20th 2021.
View our earnings forecast for MaxCyte

How has MaxCyte's stock been impacted by Coronavirus?

MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MXCT stock has increased by 616.7% and is now trading at GBX 1,075.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MXCT?

1 brokerages have issued 12-month price objectives for MaxCyte's shares. Their forecasts range from GBX 1,240 to GBX 1,240. On average, they expect MaxCyte's share price to reach GBX 1,240 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts' price targets for MaxCyte
or view top-rated stocks among Wall Street analysts.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:
  • Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 65, Pay $705.25k)
  • Mr. Ronald Evan Holtz Ph.D., CPA, Sr. VP, Chief Accounting Officer, Company Sec. & Exec. Director (Age 63, Pay $445.93k)
  • Ms. Amanda Louise Murphy C.F.A., CFA, Chief Financial Officer
  • Mr. Maher Masoud, Exec. VP & Gen. Counsel
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 60)
  • Mr. Markus J. Hunkeler, VP of Marketing
  • Dr. Claudio Dansky Ullmann M.D., Chief Medical Officer
  • Ms. Shruti Abbato, Exec. VP of Bus. Devel. for CARMA Cellular Therapies

Who are some of MaxCyte's key competitors?

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 1,075.

How much money does MaxCyte make?

MaxCyte has a market capitalization of £914.28 million and generates £26.92 million in revenue each year.

How many employees does MaxCyte have?

MaxCyte employs 65 workers across the globe.

What is MaxCyte's official website?

The official website for MaxCyte is www.maxcyte.com.

Where are MaxCyte's headquarters?

MaxCyte is headquartered at 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.

This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.